ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • ROS and toll-like receptors
  • route administration
  • Rural
  • s100
  • S100A8/A9
  • Sacral Neuromodulation
  • sacroiliac joints
  • sacroiliac joints and inflammation
  • Sacroiliitis
  • Safety
  • safety and big data
  • safety and biomarkers
  • safety and clinical trials
  • Safety and Efficacy
  • safety and growth factors
  • safety and herpes zoster subunit vaccine
  • safety and Janus kinase (JAK)
  • safety and pharmacokinetics
  • safety and registry
  • safety and sarcoidosis
  • safety and skin
  • safety and sleep
  • safety and small molecules
  • safety and spondylarthritis
  • safety and steroids
  • safety and surgery
  • safety and systemic lupus erythematosus (SLE)
  • safety and systemic sclerosis
  • safety and technology
  • safety and therapy
  • safety and thrombosis
  • safety and tocilizumab
  • safety and tofacitinib
  • safety and tofacitnib
  • safety and tolerance
  • safety and tramadol
  • safety and treatment
  • safety and treatment options
  • safety and tuberculosis
  • safety and tumor necrosis factor (TNF)
  • safety and ultrasound
  • safety and uric acid
  • safety and uveitis
  • safety and vaccines
  • safety and vasculitis
  • safety and women's health
  • safety and work
  • Safety issues
  • Safety issues and biologic drugs
  • Safety issues and rheumatoid arthritis (RA)
  • Salience
  • Salivary gland
  • salivary gland and activity score
  • salivary gland and B cells
  • salivary gland and juvenile SLE
  • salivary gland and remission
  • salivary gland and salivary hypofunction
  • salivary gland and serologic tests
  • salivary gland and treatment
  • salivary gland and ultrasonography
  • salivary gland and ultrasound
  • salivary gland and viruses
  • salivary gland biopsies
  • salivary glands and ultrasound
  • salivary hypofunction
  • salivary hypofunction and diabetes
  • salivary hypofunction and proteomics
  • salivary hypofunction and scleroderma
  • salivary hypofunction and thyroid
  • salivary hypofunction and treatment
  • salivary hypofunction and ultrasonography
  • SAPHO syndrome
  • SAPHO syndrome and ibandronate
  • SAPHO syndrome and mandibular involvement
  • SAPHO syndrome and quality of life
  • SAPHO syndrome and treatment
  • sarcoidosis
  • sarcoidosis and hiv
  • sarcoidosis and myocardial involvement
  • sarcoidosis and ocular involvement
  • sarcoidosis and off-label prescribing
  • sarcoidosis and sex bias
  • sarcoidosis and systemic sclerosis
  • sarcoidosis and thrombosis
  • sarcoidosis and tobacco use
  • sarcoidosis and treatment
  • sarcoidosis and treatment guidlelines
  • sarcoidosis and tumor necrosis factor (TNF)
  • Sarcoidosis and ultrasound
  • sarcoidosis and uveitis
  • sarcoidosis and vasculitis
  • sarcopenia
  • sarcopenia and axial spondyloarthritis
  • sarcopenia and body composition
  • sarcopenia and body mass
  • sarcopenia and frailty
  • sarcopenia and systemic vasculitides
  • Sarilumab
  • SARS-CoV-2 Antibody
  • SAT1
  • Satisfaction
  • SAVI
  • sciatica and spine involvement
  • sciatica and ultrasonography
  • Science
  • Scleredema
  • Scleredema and clinical trials
  • Scleredema and cytokines
  • Scleredema and fibroblasts
  • Scleredema and interstitial lung disease
  • Scleredema and lung
  • Scleredema and mouse model
  • Scleredema and myopathy
  • Scleredema and skin fibrosis
  • Scleredema and transplantation
  • Scleritis
  • Scleroderma
  • scleroderma and clinical trials
  • scleroderma and co-inhibitory
  • scleroderma and gastrointestinal complications
  • scleroderma and GERD
  • scleroderma and mixed connective tissue disease (MCTD)
  • scleroderma and nailfold capillaroscopy
  • scleroderma and quality of life
  • scleroderma and scleroderma-like conditions
  • scleroderma and skin
  • scleroderma and skin fibrosis
  • scleroderma and statins
  • Scleroderma and stem cells
  • scleroderma and stress
  • scleroderma and systemic lupus erythematosus (SLE)
  • scleroderma and systemic sclerosis
  • scleroderma and therapeutic targeting
  • scleroderma and therapy
  • scleroderma and thrombin inhibitors
  • scleroderma and thyroid
  • scleroderma and transforming growth factor
  • scleroderma and transplantation
  • scleroderma and treatment
  • scleroderma and treatment options
  • scleroderma and ulcers
  • scleroderma and ultrasound
  • scleroderma and wounds
  • scleroderma renal crisis
  • scleroderma-like conditions
  • scleroderma-like conditions and treatment
  • Scleroderma, Localized
  • Scleroderma, Systemic
  • Score
  • screen
  • screening
  • screening and measure
  • screening and quality improvement
  • scRNAseq
  • Scurvy
  • seasonality
  • Sec16A
  • secukinumab
  • security
  • self-efficacy
  • Self-management
  • self-management and online patient engagement
  • self-management and sex bias
  • self-management and shared dicision making
  • self-management and social support
  • self-management and spondylarthritis
  • self-management and stress
  • self-management and surgery
  • self-management and synovitis
  • self-management and systemic lupus erythematosus (SLE)
  • self-management and systemic sclerosis
  • self-management and technology
  • self-management and treatment
  • self-management and website
  • self-management and women's health
  • Senescent Cells
  • Senescent Cells and T cells
  • sensitisation
  • sensitivity and specificity
  • Sensorimotor
  • septic
  • septic arthritis
  • septic bursitis
  • serologic tests
  • serologic tests and rheumatoid arthritis
  • serologic tests and screening
  • serologic tests and sialoadenitis
  • serologic tests and socioeconomic factors
  • serologic tests and statistical methods
  • serologic tests and systemic lupus erythematosus (SLE)
  • serologic tests and systemic sclerosis
  • serologic tests and takayasu arteritis
  • serologic tests and trainee
  • Serologic tests and uveitis
  • serologic tests and vaccines
  • Serology
  • seronegative antiphospholipid syndrome
  • seronegative spondyloarthropathy
  • seronegative spondyloarthropathy and anti-TNF therapy
  • seronegative spondyloarthropathy and spine involvement
  • First |
  • « Previous Page
  • 53
  • 54
  • 55
  • 56
  • 57
  • [58]
  • 59
  • 60
  • 61
  • 62
  • 63
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology